CN113274491B - 一种用于猪流行性腹泻的rna疫苗及其构建方法 - Google Patents

一种用于猪流行性腹泻的rna疫苗及其构建方法 Download PDF

Info

Publication number
CN113274491B
CN113274491B CN202110480993.7A CN202110480993A CN113274491B CN 113274491 B CN113274491 B CN 113274491B CN 202110480993 A CN202110480993 A CN 202110480993A CN 113274491 B CN113274491 B CN 113274491B
Authority
CN
China
Prior art keywords
leu
ser
val
thr
rna vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110480993.7A
Other languages
English (en)
Other versions
CN113274491A (zh
Inventor
刘昕
赖强
王弋
吴培枫
陈怡林
谢汝祝
彭小珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Yuanbo Pharmaceutical Technology Co ltd
Original Assignee
Guangzhou Yuanbo Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Yuanbo Pharmaceutical Technology Co ltd filed Critical Guangzhou Yuanbo Pharmaceutical Technology Co ltd
Priority to CN202110480993.7A priority Critical patent/CN113274491B/zh
Publication of CN113274491A publication Critical patent/CN113274491A/zh
Application granted granted Critical
Publication of CN113274491B publication Critical patent/CN113274491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明属于RNA疫苗的技术领域,具体涉及一种用于猪流行性腹泻的RNA疫苗及其构建方法。其构建为通过选取猪源的5’UTR、3’UTR与毒株的S蛋白、终止密码子、polyA核酸序列串联,得到RNA疫苗,采用脂质纳米颗粒作为RNA疫苗的运送载体,能够快速应对当前流行野毒株的PEDV新毒株,能够高效迅速地针对变异病毒,本发明制备的猪流行性腹泻的RNA疫苗成本低、生产效率高,且能同时诱导细胞免疫与体液免疫,所制备的脂质纳米颗粒包裹RNA疫苗能够快速应对当前流行野毒株的PEDV新毒株,尤其是变异强毒株,减少了新疫苗开发的研发及生产周期,为新变异强毒株的防控提供有效的技术手段。

Description

一种用于猪流行性腹泻的RNA疫苗及其构建方法
技术领域
本发明属于RNA疫苗的技术领域,具体涉及一种用于猪流行性腹泻的RNA疫苗及其构建方法。
背景技术
猪流行性腹泻(Porcine epidemic diarrhea,PED)是一种常见的、急性、高度流行性的猪肠道病毒传染病,病原为猪流行性腹泻病毒(PEDV)。该病主要临床症状是腹泻,包括水样腹泻,以及其它包括呕吐、厌食、脱水和体重降低等症状,临床变化和症状与猪传染性胃肠炎(TGE),猪流行性腹泻是导致仔猪早期死亡的主要疫病之一。
1971年英国首次报道了该病,然后欧洲各国相继开始流行,我国于1976年首次对该病有了报道,从20世纪80年代后期开始,PED在中国各地区蔓延开来,并于1995年开始用二联灭活苗或弱毒苗进行猪流行性腹泻病毒和猪传染性胃肠炎病毒(TGEV)的联合预防。
2000年在国内开始流行,从2006年初开始,PEDV疫苗的免疫效果越来越差,免疫过的猪群照常爆发PEDV。从2010年起,高致病变异毒株在中国暴发流行,导致PED的发病率和死亡率大幅升高,严重影响中国养猪生产。病毒分离及检测数据表明本次大流行是由于变异PEDV毒株引起的,南方流行的毒株在长期传播过程中经历逐渐的基因变异,这种情况也可能造成了国内疫苗免疫失效,而且PEDV发生的突变会更多地集中在S基因,个别毒株是疫苗弱毒株或野毒株与疫苗毒株的重组病毒。
目前世界范围PEDV主要分为四种类型:亚洲经典毒株、亚洲变异毒株、美洲INDELs毒株及美洲强毒力毒株。其中亚洲经典毒株和美洲INDELs毒株为弱毒力毒株;亚洲变异毒株和美洲强毒力毒株为强毒力毒株。美洲强毒力毒株被认为来源于亚洲变异毒株。美洲INDELs毒株非常特殊,是由美洲强毒力毒株的骨架和亚洲经典毒株的S基因重组产生。在此背景下,相关科研人员针对病原及其疫苗开展了大量研究工作,也为PED的防控提供了理论依据。
早期对PED的防控主要采用组织灭活苗,但组织灭活苗病毒含量较低,免疫持久性不强,往往需要多次免疫,因此不利于规模化养殖场的大群免疫;有多种疫苗包括细胞灭活苗、弱毒疫苗以及亚单位疫苗等对毒株均有较好的免疫效果,但是PED之所以能在全球流行并给养殖户造成巨大经济损失,正是因为PEDV毒株基因型种类繁多且易发生基因变异,使得毒株毒力增强,因此现有疫苗难以发挥保护作用。国内猪流行性腹泻病毒毒株不仅已发生变异,形成新的毒株,而且毒株间存在基因差异,形成基因源多样性,这些因素都可以造成疫苗失效和疫病流行。传统的灭活苗和弱毒苗的研制需要一定的周期,疫苗的研发速度往往赶不上病毒的变异速度。临床上急需针对当前流行野毒株的PEDV新毒株疫苗。
发明内容
针对上述问题,本发明的目的在于提供一种用于猪流行性腹泻的RNA疫苗及其构建方法,通过选取猪源的5’UTR、3’UTR与毒株的S蛋白、终止密码子、polyA核酸序列串联,得到RNA疫苗,采用脂质纳米颗粒作为RNA疫苗的运送载体,能够快速应对当前流行野毒株的PEDV新毒株。
本发明的技术内容如下:
本发明提供了一种用于猪流行性腹泻的RNA疫苗,所述RNA疫苗为采用含有5’UTR、猪流行性腹泻病毒的S蛋白、终止密码子、3’UTR以及polyA核酸的序列合成;
所述疫苗还包括纳米脂质颗粒,所述纳米脂质颗粒包裹RNA疫苗;
所述纳米脂质颗粒包括BHEM-Chol、PEG5k-b-PLGA11k、PLGA11k聚合物的混合物;
所述5’UTR、3’UTR的序列选取自猪源的猪血红蛋白或猪白蛋白,所选序列的同源性在50%~100%;
所述5’UTR、3’UTR分别选自三组不同的猪血红蛋白,其核酸序列分别为序列表SEQID NO.1和SEQ ID NO.2、SEQ ID NO.3和SEQ ID NO.4、SEQ ID NO.5和SEQ ID NO.6所示的三组;
所述5’UTR、3’UTR的三组序列选自GenBank中NCBI参考序列XM_21086967.1、XM_021086966.1、M_001005208.1;
所述猪流行性腹泻病毒的S蛋白,其氨基酸序列如序列表SEQ ID NO.7所示,其核酸序列如序列表SEQ ID NO.8所示;
所述RNA疫苗的核酸序列包括如序列表SEQ ID NO.9、SEQ ID NO.10、SEQ IDNO.11所示;
所述终止密码子,为TGA、TAA、TAG的自由组合,个数为1-10个;
所述polyA中的碱基A的个数为1-200个。
本发明还提供了一种用于猪流行性腹泻的RNA疫苗的构建方法,包括如下步骤:
选取5’UTR、3’UTR、S蛋白、终止密码子、polyA核酸序列合成RNA疫苗的核酸序列构建于载体上,转染到细菌得到重组菌,将重组菌进行质粒提取得到重组质粒,将重组质粒进行酶切、转录、纯化得到RNA疫苗核酸,所述RNA疫苗的核酸序列如序列表SEQ ID NO.9、SEQID NO.10、SEQ ID NO.11所示;
所述RNA疫苗包括由脂质纳米颗粒载体包裹,所述脂质纳米颗粒的制备原料包括聚合物PEG5k-b-PLGA11k、PLGA11k和BHEM-Chol;
所述脂质纳米颗粒包裹RNA疫苗的操作为:将RNA疫苗核酸溶液与BHEM-Chol、PEG5k-b-PLGA11k、PLGA11k混合,超声得到油相-水相的初乳液,加入无核酸酶水再超声乳化得到水相-油相-水相的复乳液,将复乳液中的有机溶液去除,浓缩,即得到脂质纳米颗粒包裹的RNA疫苗;
所述RNA疫苗核酸溶液为RNA疫苗核酸使用无核酸酶水溶解得到;
所述BHEM-Chol、PEG5k-b-PLGA11k、PLGA11k使用之前分别溶于色谱级三氯甲烷溶液中。
本发明的有益效果如下:
本发明的用于猪流行性腹泻的RNA疫苗,能够高效迅速地针对变异病毒,猪流行性腹泻的RNA疫苗成本低、生产效率高,且能同时诱导细胞免疫与体液免疫,所制备的脂质纳米颗粒包裹RNA疫苗能够快速应对当前流行野毒株的PEDV新毒株,尤其是变异强毒株,减少了新疫苗开发的研发及生产周期,为新变异强毒株的防控提供有效的技术手段;
本发明的用于猪流行性腹泻的RNA疫苗的构建,选取猪源的5’UTR、3’UTR与毒株的S蛋白、终止密码子、polyA核酸序列串联,得到RNA疫苗,采用脂质纳米颗粒作为RNA疫苗的运送载体,且脂质纳米颗粒包裹RNA疫苗的使用能够高效表达,利用了纳米脂质体作为载体进行递送,脂质纳米颗粒具有核酸包封率高,能够有效转染,组织穿透性增强,细胞毒性和免疫原性低等特点,所述RNA疫苗可做到无细胞生产、且生产时无需导入有毒化学品,受微生物污染的机会也相对较低,RNA疫苗的安全性相对较高。
附图说明
图1为转录纯化后的RNA疫苗核酸的凝胶电泳图;
图2为脂质体颗粒包裹RNA疫苗的体外表达试验SDS-PAGE以及Western blot结果图;
图3为脂质体颗粒包裹RNA疫苗的抗体水平检测结果图;
图4为脂质体颗粒包裹RNA疫苗中和抗体滴度的测定结果图。
具体实施方式
以下通过具体的实施案例以及附图说明对本发明作进一步详细的描述,应理解这些实施例仅用于说明本发明而不用于限制本发明的保护范围,在阅读了本发明之后,本领域技术人员对本发明的各种等价形式的修改均落于本申请所附权利要求所限定。
若无特殊说明,本发明的所有原料和试剂均为常规市场的原料、试剂。
实施例
一种用于猪流行性腹泻的RNA疫苗及其构建:
1)重组菌构建:
选取5’UTR、3’UTR、S蛋白、终止密码子、polyA核酸序列进行人工合成RNA疫苗的DNA于pUC57载体上,无缝克隆于pUC57的EcoRV酶切位点,并转化大肠杆菌DH5α,获得PEDV-S-pUC57-DH5α;
所述S蛋白可选用来自PEDV的其他毒株,也可以是S蛋白中的一段氨基酸序列或具有50-100%同源性的氨基酸序列,操作与上相同,在此不作重复赘述;
2)重组质粒
将获得的重组菌进行摇菌,按照常规方法提取质粒,参照质粒抽提试剂盒(E.Z.N.Plasmid MiniprEppendorf Kit I)说明书进行:
取菌液于1.5mL Ep管中12000r/min离心30s,弃上清;
加250μL溶液Ⅰ/RNase A,充分重悬菌泥;
加250μL溶液Ⅱ,颠倒4~6次混匀,室温作用2min至溶液变成澄清;
加350μL溶液Ⅲ,颠倒4~6次混匀以形成白色沉淀;
转移上清至DNA吸附柱中,室温静置2min。之后12000r/min离心1min,弃液;
加入500μL的Buffer HB,12000r/min离心1min,弃液;
加入750μL的DNA Wash Buffer,12000r/min离心1min,弃液,重复该步骤一次,再空管12000r/min离心1min;
移至新的1.5mLEp管中,加入50~100μL的TE室温下放置2min,12000r/min离心1min,洗脱的质粒于-20℃保存备用,取少量于1.0%琼脂糖凝胶中低压电泳检测质粒效果。
3)酶切线性化、纯化
对重组质粒进行QuickCut MluI酶切,酶切反应体系见表1,如下:
表1酶切反应体系
将上述成分加入0.5mL的EP管中,混匀,37℃酶切15min。纯化试剂盒进行纯化回收线性化重组质粒。
根据OMEGA公司的Cycle-pure纯化试剂盒使用说明书,线性化质粒进行纯化回收,方法如下:
(1)将线性化质粒收集在一个1.5ml的EP管中;
(2)加入6倍体积的Buffer CP于装有PCR产物的EP管中,小心混匀;
(3)将上述混合液全部加至试剂盒配的有滤膜的管HiBind spin-column中,10000r/min离心1min,弃去离心出来的溶液;
(4)加入700μL SPW Buffer,等待2~3min,10000r/min离心1min,弃去离心出来的溶液;
(5)重复步骤(4);
(6)空管10000r/min离心1min;
(8)弃去下面的离心管,将柱子放入新的干净的1.5mL离心管中,在柱子中央加入50μL DNA Elution Buffer,室温下放置2min,10000r/min离心1min,收集离心管中的液体即为回收的DNA片段,经琼脂糖凝胶电泳检测后即用或-20℃冰箱保存备用。提高洗脱液的温度至55℃~80℃,有利于提高DNA的洗脱效率。
4)体外转录
采用体外转录试剂盒(mMESSAGE mMACHINETMT7 ULTRA Transcription Kit)对线性化的质粒进行体外转录。
5)纯化
采用纯化试剂盒(MEGA clearTMTranscription Clean-Up Kit)对转录的产物进行纯化处理,即得RNA疫苗(mRNA)。
取来自猪源XM_21086967.1、XM_021086966.1、M_001005208.1序列的非翻译区的三组5’UTR、3’UTR,按照以上5个步骤制备成RNA疫苗核酸,并进行凝胶电泳鉴定,如图1所示。
6)脂质纳米颗粒的制备
6.1)将-80℃冰箱保存的聚合物PEG5k-b-PLGA11k,PLGA11k和BHEM-Chol取出,平衡到室温后在干燥环境下开封,分别以60.0mg/mL,38.5mg/mL和21.0mg/mL的浓度溶于色谱级三氯甲烷溶液中;
6.2)将-80℃冰箱保存的mRNA溶液在冰上融化,使用无核酸酶水(DEPC水)调整其浓度为4mg/mL,在50mL无菌离心管中,依次加入25μL mRNA(0.1mg),100μL BHEM-Chol(2mg),350μLPEG5k-b-PLGA11k(21.875mg)和50μL PLGA11k(1.925mg);
6.3)将该离心管置于冰水中,超声探头用DEPC水冲洗后放入离心管的溶液中,在80W功率和冰水浴条件下,以超声5s停2s的方式超声乳化溶液60s,得到油相-水相的初乳液。随后,将5mLDEPC水沿管壁加入到初乳液中,并在同样条件下,以超声10s停2s的方式再次乳化60s,形成水相-油相-水相的复乳液;
6.4)将复乳液转移到DEPC处理并高压过的无菌无核酸酶100mL圆底烧瓶中,使用旋转蒸发仪在低温条件下缓慢地减压旋蒸以除去乳液中的三氯甲烷,并浓缩其水溶液体积到1mL左右,制备好的脂质纳米颗粒包裹的mRNA转移到1.5mL EP管中保存于4C冰箱中待用。
7)检测细胞转染后的PEDV-S-mRNA脂质体表达情况:
1、取24孔板,接种PK-15细胞(200000个细胞/孔),采用含10%血清无抗培养基培养18小时;
2、当细胞贴壁融合度约达60%时,在转染前一小时更换为无血清的Opti-MEM培养基,转染脂质纳米颗粒PEDV-S-mRNA(1μg RNA/孔),培养6小时;
3、将培养基替换为新鲜的培养基,培养42小时。
4、1000g离心10min,收集上清液。
取上清液,进行非还原型SDS-PAGE,然后进行Western blot。Western blot采用的一抗为抗S蛋白的鼠源单克隆抗体,二抗为抗鼠源抗体。
如图2所示,表明脂质纳米颗粒PEDV-S-mRNA能够在PK-15细胞上高效表达,该方法制备的猪流行性腹泻RNA疫苗具有良好的应用前景。
8)PEDV-S-mRNA疫苗免疫小鼠及其抗体的测定
将6-8周龄雄性BALB/c小鼠随机分为5组(每组5只):PEDV-S-mRNA1组、PEDV-S-mRNA2组、PEDV-S-mRNA3组、商品灭活疫苗组、空白对照组。采用肌内免疫,试验第1天进行初次免疫,试验第28天进行加强免疫,PEDV-S-mRNA中的各组组每次免疫剂量相同,均为20g,体积为200L,商品灭活疫苗组注射剂量也为200L、空白注射组注射等体积的PBS(pH7.2,0.01M)。分别在二免14天后进行尾部采血,收集血清,用间接ELISA法测定抗体水平。如图3所示,结果显示PEDV-S-mRNA1、PEDV-S-mRNA2、PEDV-S-mRNA3实验组产生的抗体水平高于商品化的灭活疫苗。
9)血清中和试验中中和效价及抗体滴度的测定
对第42d的血清进行血清中和试验,结果显示PEDV-S-mRNA1、PEDV-S-mRNA2、PEDV-S-mRNA3实验组及商品化灭活疫苗组的中和抗体效价均显著高于PBS对照组。其中PEDV-S-mRNA1、PEDV-S-mRNA2、PEDV-S-mRNA3实验组中的中和抗体效价与灭活疫苗组相当,如下表所示:
表2疫苗中和抗体效价表
由图4可见,抗体滴度测定试验中PEDV-S-mRNA1、PEDV-S-mRNA2、PEDV-S-mRNA3实验组及商品化灭活疫苗组中和抗体滴度均高于24,表明本发明制备的猪流行性腹泻RNA疫苗可以起到很好的保护作用,为PEDV的防控提供了有效的技术手段。
序列表
<110> 广州源博医药科技有限公司
<120> 一种用于猪流行性腹泻的RNA疫苗及其构建方法
<160> 11
<170> SIPOSequenceListing 1.0
<210> 1
<211> 62
<212> DNA
<213> Sequence Artificial
<400> 1
ggctcaggcc ctcgcagccc cgcacgcttc tggtcccgac ccagactcag aaagaaccca 60
cc 62
<210> 2
<211> 117
<212> DNA
<213> Sequence Artificial
<400> 2
gctggagcct cggagatccc cgccccgggg tggggccctc ttgcactctg cacacccccc 60
cttgcaccct gacctcctga tcgttgaata aagcctgagt gggctgcagt ctctgta 117
<210> 3
<211> 412
<212> DNA
<213> Sequence Artificial
<400> 3
gtgtgcccag ccttagggcc acagcggggg gcacgtgctg atttgccccc ttcgctcctc 60
aggagagcgc ggccggggcc tagggacttc aacgggtaga acctggggcg aggataccac 120
ttccgggggg aaggtggacg cggcgggcgg gaagcagccg gtgggaagga gacgccccgg 180
cccgagtctc cgggttccgc cacagcctgg gagccaagcg cccgccgccc agccggtcgc 240
agacagtgcg tcgcgcgccc cctgccgtct gaaggccgct gcgcatcccg gcccgcgcca 300
gccaatgagc acggcgccgg cgggcgtgcc cctcgagccc caagcataaa ggctcaggcc 360
ctcgcagccc cgcacgcttc tggtcccgac ccagactcag aaagaaccca cc 412
<210> 4
<211> 117
<212> DNA
<213> Sequence Artificial
<400> 4
gctggagcct cggagatccc cgccccgggg tggggccctc ttgcactctg cacacccccc 60
cttgcaccct gacctcctga tcgttgaata aagcctgagt gggctgcagt ctctgta 117
<210> 5
<211> 39
<212> DNA
<213> Sequence Artificial
<400> 5
accttttctc ttctatcaac cccacaagcc tttggcaca 39
<210> 6
<211> 188
<212> DNA
<213> Sequence Artificial
<400> 6
acaacacagt gacaagcatc tcagactacc ctgagaataa gagaaagaga aatgaagacc 60
tagacttatc catctctttt tcttttctgt tggttttaaa ccaacaccct gtctaaagta 120
cacaaatttc tttaaatatt ttgcctcttt tctctgtgct acaattaata aaaaaatgaa 180
aagaatct 188
<210> 7
<211> 1385
<212> PRT
<213> Sequence Artificial
<400> 7
Met Lys Ser Leu Thr Tyr Phe Trp Leu Phe Leu Pro Val Leu Ser Thr
1 5 10 15
Leu Ser Leu Pro Gln Asp Val Thr Arg Cys Ser Ala Asn Thr Asn Phe
20 25 30
Arg Arg Phe Phe Ser Lys Phe Asn Val Gln Ala Pro Ala Val Val Val
35 40 45
Leu Gly Gly Tyr Leu Pro Ile Gly Glu Asn Gln Gly Val Asn Ser Thr
50 55 60
Trp Tyr Cys Ala Gly Gln His Pro Thr Ala Ser Gly Val His Gly Ile
65 70 75 80
Phe Leu Ser His Ile Arg Gly Gly His Gly Phe Glu Ile Gly Ile Ser
85 90 95
Gln Glu Pro Phe Asp Pro Ser Gly Tyr Gln Leu Tyr Leu His Lys Ala
100 105 110
Thr Asn Gly Asn Thr Asn Ala Thr Ala Arg Leu Arg Ile Cys Gln Phe
115 120 125
Pro Ser Ile Lys Thr Leu Gly Pro Thr Ala Asn Asn Asp Val Thr Thr
130 135 140
Gly Arg Asn Cys Leu Phe Asn Lys Ala Ile Pro Ala His Met Ser Glu
145 150 155 160
His Ser Val Val Gly Ile Thr Trp Asp Asn Asp Arg Val Thr Val Phe
165 170 175
Ser Asp Lys Ile Tyr Tyr Phe Tyr Phe Lys Asn Asp Trp Ser Arg Val
180 185 190
Ala Thr Lys Cys Tyr Asn Ser Gly Gly Cys Ala Met Gln Tyr Val Tyr
195 200 205
Glu Pro Thr Tyr Tyr Met Leu Asn Val Thr Ser Ala Gly Glu Asp Gly
210 215 220
Ile Ser Tyr Gln Pro Cys Thr Ala Asn Cys Ile Gly Tyr Ala Ala Asn
225 230 235 240
Val Phe Ala Thr Glu Pro Asn Gly His Ile Pro Glu Gly Phe Ser Phe
245 250 255
Asn Asn Trp Phe Leu Leu Ser Asn Asp Ser Thr Leu Val His Gly Lys
260 265 270
Val Val Ser Asn Gln Pro Leu Leu Val Asn Cys Leu Leu Ala Ile Pro
275 280 285
Lys Ile Tyr Gly Leu Gly Gln Phe Phe Ser Phe Asn Gln Thr Ile Asp
290 295 300
Gly Val Cys Asn Gly Ala Ala Val Gln Arg Ala Pro Glu Ala Leu Arg
305 310 315 320
Phe Asn Ile Asn Asp Thr Ser Val Ile Leu Ala Glu Gly Ser Ile Val
325 330 335
Leu His Thr Ala Leu Gly Thr Asn Phe Ser Phe Val Cys Ser Asn Ser
340 345 350
Ser Asp Pro His Leu Ala Thr Phe Ala Ile Pro Leu Gly Ala Ile Gln
355 360 365
Val Pro Tyr Tyr Cys Phe Leu Lys Val Asp Thr Tyr Asn Ser Thr Val
370 375 380
Tyr Lys Phe Leu Ala Val Leu Pro Pro Thr Val Arg Glu Ile Val Ile
385 390 395 400
Thr Lys Tyr Gly Asp Val Tyr Val Asn Gly Phe Gly Tyr Leu His Leu
405 410 415
Gly Leu Leu Asp Ala Val Thr Val Asn Phe Thr Gly His Gly Thr Asp
420 425 430
Asp Asp Val Ser Gly Phe Trp Thr Ile Ala Ser Thr Asn Phe Val Asp
435 440 445
Ala Leu Ile Glu Val Gln Gly Thr Ala Ile Gln Arg Ile Leu Tyr Cys
450 455 460
Asp Asp Pro Val Ser Gln Leu Lys Cys Ser Gln Val Ser Phe Asp Leu
465 470 475 480
Asp Asp Gly Phe Tyr Pro Ile Ser Ser Thr Asn Leu Leu Ser His Glu
485 490 495
Gln Pro Thr Ser Phe Val Thr Leu Pro Ser Phe Asn Asp His Ser Phe
500 505 510
Val Asn Ile Thr Val Ser Ala Ala Phe Gly Gly His Ser Gly Ala Asn
515 520 525
Leu Ile Ala Ser Asp Thr Thr Ile Asn Gly Phe Ser Ser Phe Cys Val
530 535 540
Asp Thr Arg Gln Phe Thr Ile Ser Leu Phe Tyr Asn Val Thr Asn Ser
545 550 555 560
Tyr Gly Tyr Val Ser Lys Ser Gln Asp Ser Asn Cys Pro Phe Thr Leu
565 570 575
Gln Ser Val Asn Asp Tyr Leu Ser Phe Ser Lys Phe Cys Val Ser Thr
580 585 590
Ser Leu Leu Ala Ser Ala Cys Thr Ile Asp Leu Phe Gly Tyr Pro Glu
595 600 605
Phe Gly Ser Gly Val Lys Phe Thr Ser Leu Tyr Phe Gln Phe Thr Lys
610 615 620
Gly Glu Leu Ile Thr Gly Thr Pro Lys Pro Leu Glu Gly Val Thr Asp
625 630 635 640
Val Ser Phe Met Thr Leu Asp Val Cys Thr Lys Tyr Thr Ile Tyr Gly
645 650 655
Phe Lys Gly Glu Gly Ile Ile Thr Leu Thr Asn Ser Ser Phe Leu Ala
660 665 670
Gly Phe Tyr Tyr Thr Ser Asp Ser Gly Gln Leu Leu Ala Phe Lys Asn
675 680 685
Val Thr Ser Gly Ala Val Tyr Ser Val Thr Pro Cys Ser Phe Ser Glu
690 695 700
Gln Ala Ala Tyr Val Asp Asp Asp Ile Val Gly Val Ile Ser Ser Leu
705 710 715 720
Ser Ser Ser Thr Phe Asn Ser Thr Arg Glu Leu Pro Gly Phe Phe Tyr
725 730 735
His Ser Asn Asp Gly Ser Asn Cys Thr Glu Pro Val Leu Val Tyr Ser
740 745 750
Asn Ile Gly Val Cys Lys Ser Gly Ser Ile Gly Tyr Val Pro Ser Gln
755 760 765
Ser Gly Gln Val Lys Ile Ala Pro Thr Val Thr Gly Asn Ile Ser Ile
770 775 780
Pro Thr Asn Phe Ser Met Ser Ile Arg Thr Glu Tyr Leu Gln Leu Tyr
785 790 795 800
Asn Thr Pro Val Ser Val Asp Cys Ala Thr Tyr Val Cys Asn Gly Asn
805 810 815
Ser Arg Cys Lys Gln Leu Leu Thr Gln Tyr Thr Ala Ala Cys Lys Thr
820 825 830
Ile Glu Ser Ala Leu Gln Leu Ser Ala Arg Leu Glu Ser Ala Glu Val
835 840 845
Asn Ser Met Leu Thr Ile Ser Glu Glu Ala Leu Gln Leu Ala Thr Ile
850 855 860
Ser Ser Phe Asn Gly Asp Gly Tyr Asn Phe Thr Asn Val Leu Gly Val
865 870 875 880
Ser Val Tyr Asp Pro Ala Ser Gly Arg Val Val Gln Lys Arg Ser Phe
885 890 895
Ile Glu Asp Leu Leu Phe Asn Lys Val Val Thr Asn Gly Leu Gly Thr
900 905 910
Val Asp Glu Asp Tyr Lys Arg Cys Ser Asn Gly Arg Ser Val Ala Asp
915 920 925
Leu Val Cys Ala Gln Tyr Tyr Ser Gly Val Met Val Leu Pro Gly Val
930 935 940
Val Asp Ala Glu Lys Leu His Met Tyr Ser Ala Ser Leu Ile Gly Gly
945 950 955 960
Met Val Leu Gly Gly Phe Thr Ala Ala Ala Ala Leu Pro Phe Ser Tyr
965 970 975
Ala Val Gln Ala Arg Leu Asn Tyr Leu Ala Leu Gln Thr Asp Val Leu
980 985 990
Gln Arg Asn Gln Gln Leu Leu Ala Glu Ser Phe Asn Ser Ala Ile Gly
995 1000 1005
Asn Ile Thr Ser Ala Phe Glu Ser Val Lys Glu Ala Ile Ser Gln Thr
1010 1015 1020
Ser Lys Gly Leu Asn Thr Val Ala His Ala Leu Thr Lys Val Gln Glu
1025 1030 1035 1040
Val Val Asn Ser Gln Gly Ala Ala Leu Thr Gln Leu Thr Val Gln Leu
1045 1050 1055
Gln His Asn Phe Gln Ala Ile Ser Ser Ser Ile Asp Asp Ile Tyr Ser
1060 1065 1070
Arg Leu Asp Ile Leu Ser Ala Asp Val Gln Val Asp Arg Leu Ile Thr
1075 1080 1085
Gly Arg Leu Ser Ala Leu Asn Ala Phe Val Ala Gln Thr Leu Thr Lys
1090 1095 1100
Tyr Thr Glu Val Gln Ala Ser Arg Lys Leu Ala Gln Gln Lys Val Asn
1105 1110 1115 1120
Glu Cys Val Lys Ser Gln Ser Gln Arg Tyr Gly Phe Cys Gly Gly Asp
1125 1130 1135
Gly Glu His Ile Phe Ser Leu Val Gln Ala Ala Pro Gln Gly Leu Leu
1140 1145 1150
Phe Leu His Thr Val Leu Val Pro Gly Asp Phe Val Asn Val Ile Ala
1155 1160 1165
Ile Ala Gly Leu Cys Val Asn Asp Glu Ile Ala Leu Thr Leu Arg Glu
1170 1175 1180
Pro Gly Leu Val Leu Phe Thr His Glu Leu Gln Asn Thr Ala Thr Glu
1185 1190 1195 1200
Tyr Phe Val Ser Ser Arg Arg Met Tyr Glu Pro Arg Lys Pro Thr Val
1205 1210 1215
Gly Asp Phe Val Gln Ile Glu Ser Cys Val Val Thr Tyr Val Asn Leu
1220 1225 1230
Thr Arg Asp Gln Leu Pro Asp Val Ile Pro Asp Tyr Ile Asp Val Asn
1235 1240 1245
Lys Thr Leu Asp Glu Ile Leu Ala Ser Leu Pro Asn Arg Thr Gly Pro
1250 1255 1260
Ser Leu Ser Leu Asp Val Phe Asn Ala Thr Tyr Leu Asn Leu Thr Gly
1265 1270 1275 1280
Glu Ile Ala Asp Leu Glu Gln Arg Ser Glu Ser Leu Arg Asn Thr Thr
1285 1290 1295
Glu Glu Leu Gln Ser Leu Ile Tyr Asn Ile Asn Asn Thr Leu Val Asp
1300 1305 1310
Leu Glu Trp Leu Asn Arg Val Glu Thr Tyr Ile Lys Trp Pro Trp Trp
1315 1320 1325
Val Trp Leu Ile Ile Phe Ile Val Leu Ile Phe Val Val Ser Leu Leu
1330 1335 1340
Val Phe Cys Cys Ile Ser Thr Gly Cys Cys Gly Cys Cys Gly Cys Cys
1345 1350 1355 1360
Gly Ala Cys Phe Ser Gly Cys Cys Arg Gly Pro Arg Leu Gln Pro Tyr
1365 1370 1375
Glu Ala Phe Glu Lys Val His Val Gln
1380 1385
<210> 8
<211> 4155
<212> DNA
<213> Sequence Artificial
<400> 8
atgaagtctt taacctactt ctggttgttc ttaccagtac tttcaacact tagcctacca 60
caagatgtca ccaggtgctc agctaacact aattttaggc ggttcttttc aaaatttaat 120
gttcaggcgc ctgcagttgt tgtactgggc ggttatctac ctattggtga aaaccagggt 180
gtcaattcaa cttggtactg tgctggccaa catccaactg ctagtggcgt tcatggtatc 240
tttcttagcc atattagagg tggtcatggc tttgagattg gcatttcgca agagcctttt 300
gaccctagtg gttaccagct ttatttacat aaggctacta acggtaacac taatgctact 360
gcgcgactgc gcatttgcca gtttcctagc attaaaacat tgggccccac tgctaataat 420
gatgttacaa caggtcgtaa ctgcctattt aacaaagcca tcccagctca tatgagtgaa 480
catagtgttg tcggcataac atgggataat gatcgtgtca ctgtcttttc tgacaagatc 540
tattattttt attttaaaaa tgattggtcc cgtgttgcga caaagtgtta caacagtgga 600
ggttgtgcta tgcaatatgt ttacgaaccc acctattaca tgcttaatgt tactagtgct 660
ggtgaggatg gtatttctta tcaaccctgt acagctaatt gcattggtta tgctgccaat 720
gtatttgcta ctgagcccaa tggccacata ccagaaggtt ttagttttaa taattggttt 780
cttttgtcca atgattccac tttggtgcat ggtaaggtgg tttccaacca accattgttg 840
gtcaattgtc ttttggccat tcctaagatt tatggactag gccaattttt ctcctttaat 900
caaacgatcg atggtgtttg taatggagct gctgtgcagc gtgcaccaga ggctctgagg 960
tttaatatta atgacacctc tgtcattctt gctgaaggct caattgtact tcatactgct 1020
ttaggaacaa atttttcttt tgtttgcagt aattcctcag atcctcactt agccaccttc 1080
gccatacctc tgggtgctat ccaagtaccc tattattgtt ttcttaaagt ggatacttac 1140
aactccactg tttataaatt cttggctgtt ttacctccta ccgtcaggga aattgtcatc 1200
accaagtatg gtgatgttta tgtcaatggg tttggctact tgcatcttgg tttgttggat 1260
gctgtcacag ttaatttcac tggtcatggc actgacgatg acgtttctgg tttttggacc 1320
atagcatcga ctaattttgt tgatgcactt atcgaagttc aaggaactgc cattcagcgt 1380
attctttatt gtgatgatcc tgttagccaa ctcaagtgtt ctcaggtttc atttgacctt 1440
gacgatggtt tttaccccat ttcctctaca aaccttctga gtcatgaaca gccaacttct 1500
tttgttactt tgccatcatt taatgatcat tcttttgtta atattactgt ctctgctgct 1560
tttggtggtc atagtggtgc caaccttatt gcatctgaca ctactatcaa tgggtttagt 1620
tctttctgtg ttgacactag acaatttacc atttcactgt tttataatgt tacaaacagt 1680
tatggttatg tgtctaaatc acaggacagt aattgccctt tcaccttgca atctgttaat 1740
gattacctgt cttttagcaa attttgtgtt tctaccagcc ttttggctag tgcctgtacc 1800
atagatctct ttggttaccc tgagtttggt agtggtgtta agttcacgtc cctttacttt 1860
caattcacaa agggtgagtt gattactggc acgcctaaac cacttgaagg tgttacggac 1920
gtttctttta tgactctgga tgtgtgtacc aagtatacta tctatggctt taaaggtgag 1980
ggtatcatta cccttacaaa ttctagcttt ttggcaggtt tttattatac atctgattct 2040
ggacagttgt tagcttttaa gaatgtcact agtggtgctg tttattctgt tacgccatgt 2100
tctttttcag agcaggctgc atatgttgat gatgatatag tgggtgttat ttctagtttg 2160
tctagctcca cttttaacag tactagggag ttgcctggtt tcttctacca ttctaatgat 2220
ggctctaatt gtacagagcc tgtgttggtg tatagtaaca taggtgtttg taaatctggc 2280
agtattggct acgtcccatc tcagtctggc caagtcaaga ttgcacccac ggttactggg 2340
aatattagta ttcccaccaa ctttagtatg agtattagga cagaatattt acagctttac 2400
aacacgcctg ttagtgttga ttgtgctaca tatgtttgta atggtaactc tcgttgtaaa 2460
caattactca cccagtacac tgcagcatgt aagaccatag agtcagcatt acaactcagc 2520
gctaggcttg agtctgctga agtcaactct atgcttacta tttctgaaga ggctctacag 2580
ttagctacca tcagttcgtt taatggtgat ggatataatt ttactaatgt gctgggtgtt 2640
tccgtgtatg accctgcaag tggcagggtg gtacaaaaaa ggtctttcat tgaagacctg 2700
ctttttaata aagtggttac taatggcctt ggtactgttg atgaagacta taagcgctgt 2760
tctaatggcc gctctgtggc agatttagtc tgtgcgcagt attactctgg tgtcatggta 2820
ctacctggtg ttgttgacgc tgagaagctt catatgtata gtgcgtctct catcggtggt 2880
atggtgctag gaggttttac tgcagcagcg gcattgcctt ttagctatgc tgttcaagcg 2940
agactcaatt atcttgcttt acagacggat gttctacagc ggaaccagca attgcttgct 3000
gagtctttta attctgctat tggtaatata acttcagcct ttgagagtgt taaagaggct 3060
attagtcaaa cttctaaggg tttgaacact gtggctcatg cgcttactaa ggtccaagag 3120
gttgttaatt cgcagggtgc agctttgacc caacttaccg tacagctgca acacaacttc 3180
caagccattt ctagttctat tgatgacatt tactcccgac ttgacattct ttcagccgat 3240
gttcaggtag accgtctcat caccggcaga ttatcagcac ttaatgcttt tgttgctcaa 3300
acccttacta agtatactga ggttcaggct agcaggaaac tagcacagca aaaggttaat 3360
gagtgcgtta aatcgcaatc tcagcgttac ggtttttgtg gtggtgatgg cgagcacatt 3420
ttctctctgg tacaggccgc acctcaaggc ctgctgttct tacacacagt acttgtaccg 3480
ggtgattttg taaatgttat tgccatcgct ggcttatgtg ttaacgatga aattgccctg 3540
actctacgtg agcctggctt agtcttgttt acgcatgaac ttcaaaatac tgcgacggaa 3600
tattttgttt catcgcgacg tatgtatgaa cctagaaaac ctaccgttgg tgattttgtt 3660
caaattgaga gttgtgtggt cacctatgtc aatttgacta gagaccaact accagatgta 3720
atcccagatt acatcgatgt taacaaaaca cttgatgaga ttttagcttc tctgcccaat 3780
agaactggtc caagtctttc tctagatgtt tttaatgcca cttatcttaa tcttactggt 3840
gaaattgcag atttagagca gcgttcagag tctctccgta atactacaga agagcttcaa 3900
agtcttatat ataatatcaa caacacacta gttgaccttg agtggctcaa ccgagttgag 3960
acatatatca agtggccgtg gtgggtttgg ttgattattt ttattgttct catctttgtt 4020
gtgtcattac tagtgttctg ctgcatttcc acgggttgtt gtggatgctg cggctgctgt 4080
ggtgcttgtt tttcaggttg ttgtaggggt cctagacttc aaccttacga agcttttgaa 4140
aaggtccacg tgcag 4155
<210> 9
<211> 4413
<212> DNA
<213> Sequence Artificial
<400> 9
ggctcaggcc ctcgcagccc cgcacgcttc tggtcccgac ccagactcag aaagaaccca 60
ccatgaagtc tttaacctac ttctggttgt tcttaccagt actttcaaca cttagcctac 120
cacaagatgt caccaggtgc tcagctaaca ctaattttag gcggttcttt tcaaaattta 180
atgttcaggc gcctgcagtt gttgtactgg gcggttatct acctattggt gaaaaccagg 240
gtgtcaattc aacttggtac tgtgctggcc aacatccaac tgctagtggc gttcatggta 300
tctttcttag ccatattaga ggtggtcatg gctttgagat tggcatttcg caagagcctt 360
ttgaccctag tggttaccag ctttatttac ataaggctac taacggtaac actaatgcta 420
ctgcgcgact gcgcatttgc cagtttccta gcattaaaac attgggcccc actgctaata 480
atgatgttac aacaggtcgt aactgcctat ttaacaaagc catcccagct catatgagtg 540
aacatagtgt tgtcggcata acatgggata atgatcgtgt cactgtcttt tctgacaaga 600
tctattattt ttattttaaa aatgattggt cccgtgttgc gacaaagtgt tacaacagtg 660
gaggttgtgc tatgcaatat gtttacgaac ccacctatta catgcttaat gttactagtg 720
ctggtgagga tggtatttct tatcaaccct gtacagctaa ttgcattggt tatgctgcca 780
atgtatttgc tactgagccc aatggccaca taccagaagg ttttagtttt aataattggt 840
ttcttttgtc caatgattcc actttggtgc atggtaaggt ggtttccaac caaccattgt 900
tggtcaattg tcttttggcc attcctaaga tttatggact aggccaattt ttctccttta 960
atcaaacgat cgatggtgtt tgtaatggag ctgctgtgca gcgtgcacca gaggctctga 1020
ggtttaatat taatgacacc tctgtcattc ttgctgaagg ctcaattgta cttcatactg 1080
ctttaggaac aaatttttct tttgtttgca gtaattcctc agatcctcac ttagccacct 1140
tcgccatacc tctgggtgct atccaagtac cctattattg ttttcttaaa gtggatactt 1200
acaactccac tgtttataaa ttcttggctg ttttacctcc taccgtcagg gaaattgtca 1260
tcaccaagta tggtgatgtt tatgtcaatg ggtttggcta cttgcatctt ggtttgttgg 1320
atgctgtcac agttaatttc actggtcatg gcactgacga tgacgtttct ggtttttgga 1380
ccatagcatc gactaatttt gttgatgcac ttatcgaagt tcaaggaact gccattcagc 1440
gtattcttta ttgtgatgat cctgttagcc aactcaagtg ttctcaggtt tcatttgacc 1500
ttgacgatgg tttttacccc atttcctcta caaaccttct gagtcatgaa cagccaactt 1560
cttttgttac tttgccatca tttaatgatc attcttttgt taatattact gtctctgctg 1620
cttttggtgg tcatagtggt gccaacctta ttgcatctga cactactatc aatgggttta 1680
gttctttctg tgttgacact agacaattta ccatttcact gttttataat gttacaaaca 1740
gttatggtta tgtgtctaaa tcacaggaca gtaattgccc tttcaccttg caatctgtta 1800
atgattacct gtcttttagc aaattttgtg tttctaccag ccttttggct agtgcctgta 1860
ccatagatct ctttggttac cctgagtttg gtagtggtgt taagttcacg tccctttact 1920
ttcaattcac aaagggtgag ttgattactg gcacgcctaa accacttgaa ggtgttacgg 1980
acgtttcttt tatgactctg gatgtgtgta ccaagtatac tatctatggc tttaaaggtg 2040
agggtatcat tacccttaca aattctagct ttttggcagg tttttattat acatctgatt 2100
ctggacagtt gttagctttt aagaatgtca ctagtggtgc tgtttattct gttacgccat 2160
gttctttttc agagcaggct gcatatgttg atgatgatat agtgggtgtt atttctagtt 2220
tgtctagctc cacttttaac agtactaggg agttgcctgg tttcttctac cattctaatg 2280
atggctctaa ttgtacagag cctgtgttgg tgtatagtaa cataggtgtt tgtaaatctg 2340
gcagtattgg ctacgtccca tctcagtctg gccaagtcaa gattgcaccc acggttactg 2400
ggaatattag tattcccacc aactttagta tgagtattag gacagaatat ttacagcttt 2460
acaacacgcc tgttagtgtt gattgtgcta catatgtttg taatggtaac tctcgttgta 2520
aacaattact cacccagtac actgcagcat gtaagaccat agagtcagca ttacaactca 2580
gcgctaggct tgagtctgct gaagtcaact ctatgcttac tatttctgaa gaggctctac 2640
agttagctac catcagttcg tttaatggtg atggatataa ttttactaat gtgctgggtg 2700
tttccgtgta tgaccctgca agtggcaggg tggtacaaaa aaggtctttc attgaagacc 2760
tgctttttaa taaagtggtt actaatggcc ttggtactgt tgatgaagac tataagcgct 2820
gttctaatgg ccgctctgtg gcagatttag tctgtgcgca gtattactct ggtgtcatgg 2880
tactacctgg tgttgttgac gctgagaagc ttcatatgta tagtgcgtct ctcatcggtg 2940
gtatggtgct aggaggtttt actgcagcag cggcattgcc ttttagctat gctgttcaag 3000
cgagactcaa ttatcttgct ttacagacgg atgttctaca gcggaaccag caattgcttg 3060
ctgagtcttt taattctgct attggtaata taacttcagc ctttgagagt gttaaagagg 3120
ctattagtca aacttctaag ggtttgaaca ctgtggctca tgcgcttact aaggtccaag 3180
aggttgttaa ttcgcagggt gcagctttga cccaacttac cgtacagctg caacacaact 3240
tccaagccat ttctagttct attgatgaca tttactcccg acttgacatt ctttcagccg 3300
atgttcaggt agaccgtctc atcaccggca gattatcagc acttaatgct tttgttgctc 3360
aaacccttac taagtatact gaggttcagg ctagcaggaa actagcacag caaaaggtta 3420
atgagtgcgt taaatcgcaa tctcagcgtt acggtttttg tggtggtgat ggcgagcaca 3480
ttttctctct ggtacaggcc gcacctcaag gcctgctgtt cttacacaca gtacttgtac 3540
cgggtgattt tgtaaatgtt attgccatcg ctggcttatg tgttaacgat gaaattgccc 3600
tgactctacg tgagcctggc ttagtcttgt ttacgcatga acttcaaaat actgcgacgg 3660
aatattttgt ttcatcgcga cgtatgtatg aacctagaaa acctaccgtt ggtgattttg 3720
ttcaaattga gagttgtgtg gtcacctatg tcaatttgac tagagaccaa ctaccagatg 3780
taatcccaga ttacatcgat gttaacaaaa cacttgatga gattttagct tctctgccca 3840
atagaactgg tccaagtctt tctctagatg tttttaatgc cacttatctt aatcttactg 3900
gtgaaattgc agatttagag cagcgttcag agtctctccg taatactaca gaagagcttc 3960
aaagtcttat atataatatc aacaacacac tagttgacct tgagtggctc aaccgagttg 4020
agacatatat caagtggccg tggtgggttt ggttgattat ttttattgtt ctcatctttg 4080
ttgtgtcatt actagtgttc tgctgcattt ccacgggttg ttgtggatgc tgcggctgct 4140
gtggtgcttg tttttcaggt tgttgtaggg gtcctagact tcaaccttac gaagcttttg 4200
aaaaggtcca cgtgcagtga taataagctg gagcctcgga gatccccgcc ccggggtggg 4260
gccctcttgc actctgcaca cccccccttg caccctgacc tcctgatcgt tgaataaagc 4320
ctgagtgggc tgcagtctct gtaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4380
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 4413
<210> 10
<211> 4760
<212> DNA
<213> Sequence Artificial
<400> 10
gtgtgcccag ccttagggcc acagcggggg gcacgtgctg atttgccccc ttcgctcctc 60
aggagagcgc ggccggggcc tagggacttc aacgggtaga acctggggcg aggataccac 120
ttccgggggg aaggtggacg cggcgggcgg gaagcagccg gtgggaagga gacgccccgg 180
cccgagtctc cgggttccgc cacagcctgg gagccaagcg cccgccgccc agccggtcgc 240
agacagtgcg tcgcgcgccc cctgccgtct gaaggccgct gcgcatcccg gcccgcgcca 300
gccaatgagc acggcgccgg cgggcgtgcc cctcgagccc caagcataaa ggctcaggcc 360
ctcgcagccc cgcacgcttc tggtcccgac ccagactcag aaagaaccca ccatgaagtc 420
tttaacctac ttctggttgt tcttaccagt actttcaaca cttagcctac cacaagatgt 480
caccaggtgc tcagctaaca ctaattttag gcggttcttt tcaaaattta atgttcaggc 540
gcctgcagtt gttgtactgg gcggttatct acctattggt gaaaaccagg gtgtcaattc 600
aacttggtac tgtgctggcc aacatccaac tgctagtggc gttcatggta tctttcttag 660
ccatattaga ggtggtcatg gctttgagat tggcatttcg caagagcctt ttgaccctag 720
tggttaccag ctttatttac ataaggctac taacggtaac actaatgcta ctgcgcgact 780
gcgcatttgc cagtttccta gcattaaaac attgggcccc actgctaata atgatgttac 840
aacaggtcgt aactgcctat ttaacaaagc catcccagct catatgagtg aacatagtgt 900
tgtcggcata acatgggata atgatcgtgt cactgtcttt tctgacaaga tctattattt 960
ttattttaaa aatgattggt cccgtgttgc gacaaagtgt tacaacagtg gaggttgtgc 1020
tatgcaatat gtttacgaac ccacctatta catgcttaat gttactagtg ctggtgagga 1080
tggtatttct tatcaaccct gtacagctaa ttgcattggt tatgctgcca atgtatttgc 1140
tactgagccc aatggccaca taccagaagg ttttagtttt aataattggt ttcttttgtc 1200
caatgattcc actttggtgc atggtaaggt ggtttccaac caaccattgt tggtcaattg 1260
tcttttggcc attcctaaga tttatggact aggccaattt ttctccttta atcaaacgat 1320
cgatggtgtt tgtaatggag ctgctgtgca gcgtgcacca gaggctctga ggtttaatat 1380
taatgacacc tctgtcattc ttgctgaagg ctcaattgta cttcatactg ctttaggaac 1440
aaatttttct tttgtttgca gtaattcctc agatcctcac ttagccacct tcgccatacc 1500
tctgggtgct atccaagtac cctattattg ttttcttaaa gtggatactt acaactccac 1560
tgtttataaa ttcttggctg ttttacctcc taccgtcagg gaaattgtca tcaccaagta 1620
tggtgatgtt tatgtcaatg ggtttggcta cttgcatctt ggtttgttgg atgctgtcac 1680
agttaatttc actggtcatg gcactgacga tgacgtttct ggtttttgga ccatagcatc 1740
gactaatttt gttgatgcac ttatcgaagt tcaaggaact gccattcagc gtattcttta 1800
ttgtgatgat cctgttagcc aactcaagtg ttctcaggtt tcatttgacc ttgacgatgg 1860
tttttacccc atttcctcta caaaccttct gagtcatgaa cagccaactt cttttgttac 1920
tttgccatca tttaatgatc attcttttgt taatattact gtctctgctg cttttggtgg 1980
tcatagtggt gccaacctta ttgcatctga cactactatc aatgggttta gttctttctg 2040
tgttgacact agacaattta ccatttcact gttttataat gttacaaaca gttatggtta 2100
tgtgtctaaa tcacaggaca gtaattgccc tttcaccttg caatctgtta atgattacct 2160
gtcttttagc aaattttgtg tttctaccag ccttttggct agtgcctgta ccatagatct 2220
ctttggttac cctgagtttg gtagtggtgt taagttcacg tccctttact ttcaattcac 2280
aaagggtgag ttgattactg gcacgcctaa accacttgaa ggtgttacgg acgtttcttt 2340
tatgactctg gatgtgtgta ccaagtatac tatctatggc tttaaaggtg agggtatcat 2400
tacccttaca aattctagct ttttggcagg tttttattat acatctgatt ctggacagtt 2460
gttagctttt aagaatgtca ctagtggtgc tgtttattct gttacgccat gttctttttc 2520
agagcaggct gcatatgttg atgatgatat agtgggtgtt atttctagtt tgtctagctc 2580
cacttttaac agtactaggg agttgcctgg tttcttctac cattctaatg atggctctaa 2640
ttgtacagag cctgtgttgg tgtatagtaa cataggtgtt tgtaaatctg gcagtattgg 2700
ctacgtccca tctcagtctg gccaagtcaa gattgcaccc acggttactg ggaatattag 2760
tattcccacc aactttagta tgagtattag gacagaatat ttacagcttt acaacacgcc 2820
tgttagtgtt gattgtgcta catatgtttg taatggtaac tctcgttgta aacaattact 2880
cacccagtac actgcagcat gtaagaccat agagtcagca ttacaactca gcgctaggct 2940
tgagtctgct gaagtcaact ctatgcttac tatttctgaa gaggctctac agttagctac 3000
catcagttcg tttaatggtg atggatataa ttttactaat gtgctgggtg tttccgtgta 3060
tgaccctgca agtggcaggg tggtacaaaa aaggtctttc attgaagacc tgctttttaa 3120
taaagtggtt actaatggcc ttggtactgt tgatgaagac tataagcgct gttctaatgg 3180
ccgctctgtg gcagatttag tctgtgcgca gtattactct ggtgtcatgg tactacctgg 3240
tgttgttgac gctgagaagc ttcatatgta tagtgcgtct ctcatcggtg gtatggtgct 3300
aggaggtttt actgcagcag cggcattgcc ttttagctat gctgttcaag cgagactcaa 3360
ttatcttgct ttacagacgg atgttctaca gcggaaccag caattgcttg ctgagtcttt 3420
taattctgct attggtaata taacttcagc ctttgagagt gttaaagagg ctattagtca 3480
aacttctaag ggtttgaaca ctgtggctca tgcgcttact aaggtccaag aggttgttaa 3540
ttcgcagggt gcagctttga cccaacttac cgtacagctg caacacaact tccaagccat 3600
ttctagttct attgatgaca tttactcccg acttgacatt ctttcagccg atgttcaggt 3660
agaccgtctc atcaccggca gattatcagc acttaatgct tttgttgctc aaacccttac 3720
taagtatact gaggttcagg ctagcaggaa actagcacag caaaaggtta atgagtgcgt 3780
taaatcgcaa tctcagcgtt acggtttttg tggtggtgat ggcgagcaca ttttctctct 3840
ggtacaggcc gcacctcaag gcctgctgtt cttacacaca gtacttgtac cgggtgattt 3900
tgtaaatgtt attgccatcg ctggcttatg tgttaacgat gaaattgccc tgactctacg 3960
tgagcctggc ttagtcttgt ttacgcatga acttcaaaat actgcgacgg aatattttgt 4020
ttcatcgcga cgtatgtatg aacctagaaa acctaccgtt ggtgattttg ttcaaattga 4080
gagttgtgtg gtcacctatg tcaatttgac tagagaccaa ctaccagatg taatcccaga 4140
ttacatcgat gttaacaaaa cacttgatga gattttagct tctctgccca atagaactgg 4200
tccaagtctt tctctagatg tttttaatgc cacttatctt aatcttactg gtgaaattgc 4260
agatttagag cagcgttcag agtctctccg taatactaca gaagagcttc aaagtcttat 4320
atataatatc aacaacacac tagttgacct tgagtggctc aaccgagttg agacatatat 4380
caagtggccg tggtgggttt ggttgattat ttttattgtt ctcatctttg ttgtgtcatt 4440
actagtgttc tgctgcattt ccacgggttg ttgtggatgc tgcggctgct gtggtgcttg 4500
tttttcaggt tgttgtaggg gtcctagact tcaaccttac gaagcttttg aaaaggtcca 4560
cgtgcagtga tgagctggag cctcggagat ccccgccccg gggtggggcc ctcttgcact 4620
ctgcacaccc ccccttgcac cctgacctcc tgatcgttga ataaagcctg agtgggctgc 4680
agtctctgta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4740
aaaaaaaaaa aaaaaaaaaa 4760
<210> 11
<211> 4458
<212> DNA
<213> Sequence Artificial
<400> 11
accttttctc ttctatcaac cccacaagcc tttggcacaa tgaagtcttt aacctacttc 60
tggttgttct taccagtact ttcaacactt agcctaccac aagatgtcac caggtgctca 120
gctaacacta attttaggcg gttcttttca aaatttaatg ttcaggcgcc tgcagttgtt 180
gtactgggcg gttatctacc tattggtgaa aaccagggtg tcaattcaac ttggtactgt 240
gctggccaac atccaactgc tagtggcgtt catggtatct ttcttagcca tattagaggt 300
ggtcatggct ttgagattgg catttcgcaa gagccttttg accctagtgg ttaccagctt 360
tatttacata aggctactaa cggtaacact aatgctactg cgcgactgcg catttgccag 420
tttcctagca ttaaaacatt gggccccact gctaataatg atgttacaac aggtcgtaac 480
tgcctattta acaaagccat cccagctcat atgagtgaac atagtgttgt cggcataaca 540
tgggataatg atcgtgtcac tgtcttttct gacaagatct attattttta ttttaaaaat 600
gattggtccc gtgttgcgac aaagtgttac aacagtggag gttgtgctat gcaatatgtt 660
tacgaaccca cctattacat gcttaatgtt actagtgctg gtgaggatgg tatttcttat 720
caaccctgta cagctaattg cattggttat gctgccaatg tatttgctac tgagcccaat 780
ggccacatac cagaaggttt tagttttaat aattggtttc ttttgtccaa tgattccact 840
ttggtgcatg gtaaggtggt ttccaaccaa ccattgttgg tcaattgtct tttggccatt 900
cctaagattt atggactagg ccaatttttc tcctttaatc aaacgatcga tggtgtttgt 960
aatggagctg ctgtgcagcg tgcaccagag gctctgaggt ttaatattaa tgacacctct 1020
gtcattcttg ctgaaggctc aattgtactt catactgctt taggaacaaa tttttctttt 1080
gtttgcagta attcctcaga tcctcactta gccaccttcg ccatacctct gggtgctatc 1140
caagtaccct attattgttt tcttaaagtg gatacttaca actccactgt ttataaattc 1200
ttggctgttt tacctcctac cgtcagggaa attgtcatca ccaagtatgg tgatgtttat 1260
gtcaatgggt ttggctactt gcatcttggt ttgttggatg ctgtcacagt taatttcact 1320
ggtcatggca ctgacgatga cgtttctggt ttttggacca tagcatcgac taattttgtt 1380
gatgcactta tcgaagttca aggaactgcc attcagcgta ttctttattg tgatgatcct 1440
gttagccaac tcaagtgttc tcaggtttca tttgaccttg acgatggttt ttaccccatt 1500
tcctctacaa accttctgag tcatgaacag ccaacttctt ttgttacttt gccatcattt 1560
aatgatcatt cttttgttaa tattactgtc tctgctgctt ttggtggtca tagtggtgcc 1620
aaccttattg catctgacac tactatcaat gggtttagtt ctttctgtgt tgacactaga 1680
caatttacca tttcactgtt ttataatgtt acaaacagtt atggttatgt gtctaaatca 1740
caggacagta attgcccttt caccttgcaa tctgttaatg attacctgtc ttttagcaaa 1800
ttttgtgttt ctaccagcct tttggctagt gcctgtacca tagatctctt tggttaccct 1860
gagtttggta gtggtgttaa gttcacgtcc ctttactttc aattcacaaa gggtgagttg 1920
attactggca cgcctaaacc acttgaaggt gttacggacg tttcttttat gactctggat 1980
gtgtgtacca agtatactat ctatggcttt aaaggtgagg gtatcattac ccttacaaat 2040
tctagctttt tggcaggttt ttattataca tctgattctg gacagttgtt agcttttaag 2100
aatgtcacta gtggtgctgt ttattctgtt acgccatgtt ctttttcaga gcaggctgca 2160
tatgttgatg atgatatagt gggtgttatt tctagtttgt ctagctccac ttttaacagt 2220
actagggagt tgcctggttt cttctaccat tctaatgatg gctctaattg tacagagcct 2280
gtgttggtgt atagtaacat aggtgtttgt aaatctggca gtattggcta cgtcccatct 2340
cagtctggcc aagtcaagat tgcacccacg gttactggga atattagtat tcccaccaac 2400
tttagtatga gtattaggac agaatattta cagctttaca acacgcctgt tagtgttgat 2460
tgtgctacat atgtttgtaa tggtaactct cgttgtaaac aattactcac ccagtacact 2520
gcagcatgta agaccataga gtcagcatta caactcagcg ctaggcttga gtctgctgaa 2580
gtcaactcta tgcttactat ttctgaagag gctctacagt tagctaccat cagttcgttt 2640
aatggtgatg gatataattt tactaatgtg ctgggtgttt ccgtgtatga ccctgcaagt 2700
ggcagggtgg tacaaaaaag gtctttcatt gaagacctgc tttttaataa agtggttact 2760
aatggccttg gtactgttga tgaagactat aagcgctgtt ctaatggccg ctctgtggca 2820
gatttagtct gtgcgcagta ttactctggt gtcatggtac tacctggtgt tgttgacgct 2880
gagaagcttc atatgtatag tgcgtctctc atcggtggta tggtgctagg aggttttact 2940
gcagcagcgg cattgccttt tagctatgct gttcaagcga gactcaatta tcttgcttta 3000
cagacggatg ttctacagcg gaaccagcaa ttgcttgctg agtcttttaa ttctgctatt 3060
ggtaatataa cttcagcctt tgagagtgtt aaagaggcta ttagtcaaac ttctaagggt 3120
ttgaacactg tggctcatgc gcttactaag gtccaagagg ttgttaattc gcagggtgca 3180
gctttgaccc aacttaccgt acagctgcaa cacaacttcc aagccatttc tagttctatt 3240
gatgacattt actcccgact tgacattctt tcagccgatg ttcaggtaga ccgtctcatc 3300
accggcagat tatcagcact taatgctttt gttgctcaaa cccttactaa gtatactgag 3360
gttcaggcta gcaggaaact agcacagcaa aaggttaatg agtgcgttaa atcgcaatct 3420
cagcgttacg gtttttgtgg tggtgatggc gagcacattt tctctctggt acaggccgca 3480
cctcaaggcc tgctgttctt acacacagta cttgtaccgg gtgattttgt aaatgttatt 3540
gccatcgctg gcttatgtgt taacgatgaa attgccctga ctctacgtga gcctggctta 3600
gtcttgttta cgcatgaact tcaaaatact gcgacggaat attttgtttc atcgcgacgt 3660
atgtatgaac ctagaaaacc taccgttggt gattttgttc aaattgagag ttgtgtggtc 3720
acctatgtca atttgactag agaccaacta ccagatgtaa tcccagatta catcgatgtt 3780
aacaaaacac ttgatgagat tttagcttct ctgcccaata gaactggtcc aagtctttct 3840
ctagatgttt ttaatgccac ttatcttaat cttactggtg aaattgcaga tttagagcag 3900
cgttcagagt ctctccgtaa tactacagaa gagcttcaaa gtcttatata taatatcaac 3960
aacacactag ttgaccttga gtggctcaac cgagttgaga catatatcaa gtggccgtgg 4020
tgggtttggt tgattatttt tattgttctc atctttgttg tgtcattact agtgttctgc 4080
tgcatttcca cgggttgttg tggatgctgc ggctgctgtg gtgcttgttt ttcaggttgt 4140
tgtaggggtc ctagacttca accttacgaa gcttttgaaa aggtccacgt gcagtgatga 4200
acaacacagt gacaagcatc tcagactacc ctgagaataa gagaaagaga aatgaagacc 4260
tagacttatc catctctttt tcttttctgt tggttttaaa ccaacaccct gtctaaagta 4320
cacaaatttc tttaaatatt ttgcctcttt tctctgtgct acaattaata aaaaaatgaa 4380
aagaatctaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4440
aaaaaaaaaa aaaaaaaa 4458

Claims (1)

1.一种用于猪流行性腹泻的RNA疫苗的构建方法,其特征在于,包括如下步骤:
a)选取5’UTR、3’UTR、S蛋白、终止密码子、polyA核酸序列合成RNA疫苗的核酸序列构建于载体上,转染到细菌得到重组菌,将重组菌进行质粒提取得到重组质粒,将重组质粒进行酶切、转录、纯化得到RNA疫苗核酸,所述RNA疫苗核酸的序列如序列表SEQ ID NO.9、SEQ IDNO.10、SEQ ID NO.11之一所示;
b)使用脂质纳米颗粒包裹RNA疫苗核酸:步骤为将RNA疫苗核酸溶液与BHEM-Chol、PEG5k-b-PLGA11k、PLGA11k混合,超声得到油相-水相的初乳液,加入无核酸酶水再超声乳化得到水相-油相-水相的复乳液,将复乳液中的有机溶液去除,浓缩,即得到脂质纳米颗粒包裹的RNA疫苗。
CN202110480993.7A 2021-04-30 2021-04-30 一种用于猪流行性腹泻的rna疫苗及其构建方法 Active CN113274491B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110480993.7A CN113274491B (zh) 2021-04-30 2021-04-30 一种用于猪流行性腹泻的rna疫苗及其构建方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110480993.7A CN113274491B (zh) 2021-04-30 2021-04-30 一种用于猪流行性腹泻的rna疫苗及其构建方法

Publications (2)

Publication Number Publication Date
CN113274491A CN113274491A (zh) 2021-08-20
CN113274491B true CN113274491B (zh) 2024-04-30

Family

ID=77277868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110480993.7A Active CN113274491B (zh) 2021-04-30 2021-04-30 一种用于猪流行性腹泻的rna疫苗及其构建方法

Country Status (1)

Country Link
CN (1) CN113274491B (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107088A2 (en) * 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2019148101A1 (en) * 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CN110167587A (zh) * 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
CN110392577A (zh) * 2017-03-17 2019-10-29 库尔维科公司 用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167587A (zh) * 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
WO2018107088A2 (en) * 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
CN110392577A (zh) * 2017-03-17 2019-10-29 库尔维科公司 用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
WO2019148101A1 (en) * 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Field trials evaluating the efficacy of porcine epidemic diarrhea vaccine, RNA (Harrisvaccine) in the Philippines;K Sawattrakool等;Tropical Animal Health and Production;第52卷(第5期);2743-2747 *
In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance;Yue Zhang等;Biomaterials;第217卷;1-11 *
The dawn of mRNA vaccines: The COVID-19 case;Rein Verbeke等;Journal of Controlled Release;第333卷;511-520 *

Also Published As

Publication number Publication date
CN113274491A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
WO2014183548A1 (zh) 一种ev71病毒样颗粒及其制备方法与应用
CN112175086B (zh) 一种抗猪流行性腹泻病毒nsp13蛋白的单克隆抗体及应用
CN113845576B (zh) 重组猫疱疹病毒1型gB-gD蛋白及其应用
CN107098974A (zh) 一种融合蛋白及其应用
CN113230394B (zh) 一种用于牛病毒性腹泻的rna疫苗及其构建方法
CN111675758B (zh) 一种抗羊包虫病感染的基因工程亚单位疫苗
CN113403329B (zh) 一种用于猫冠状病毒的rna疫苗及其构建方法
CN114395574B (zh) 一种猪流行性腹泻病毒融合蛋白及其编码基因与应用
CN112142851B (zh) 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用
CN113817040A (zh) 一种细粒棘球蚴重组蛋白及其制备方法
CN113862284A (zh) 一种编码重组禽流感病毒ha蛋白的基因、病毒样颗粒、疫苗及制备与应用
CN111500586B (zh) 特异结合狂犬病毒l蛋白加帽区的核酸适配体及其应用
CN113274491B (zh) 一种用于猪流行性腹泻的rna疫苗及其构建方法
CN111378017B (zh) 小反刍兽疫病毒的亚单位f蛋白及其制备方法和应用
CN111607605A (zh) 一种多价表位和亚单位疫苗的构建方法
CN116240222A (zh) 一种密码子优化的牛病毒性腹泻病毒1型e2蛋白基因及其应用
CN105420174A (zh) 一种表达重组vegf融合蛋白的基因工程菌的构建
CN114317571A (zh) 一种病毒样颗粒及其制备方法和应用
CN111378016B (zh) 小反刍兽疫病毒的亚单位h蛋白及其制备方法和应用
CN108715607B (zh) 重组霍乱毒素b亚基蛋白、pedv灭活疫苗及制备与应用
CN109295014B (zh) 一种非典型猪瘟病毒e2蛋白重组杆状病毒及其制备方法和应用
CN112679616A (zh) 一种牙鲆弹状病毒基因工程亚单位疫苗
CN107827986B (zh) 猪O/Mya98和O/PanAsia型口蹄疫基因工程灭活疫苗
CN111732667B (zh) 小反刍兽疫病毒基因工程亚单位疫苗
CN110747215A (zh) 一种高效表达猪瘟e2蛋白的重组杆状病毒及其构建方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant